XPO5

Across TCGA pan-cancer cohorts, XPO5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated XPO5 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher XPO5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated XPO5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where XPO5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.872	0.580	<.001	58	view →
LUAD	OS	Median	All	0.650	1.000	.002	12	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	11	view →
PDAC	OS	Tertile	All	0.401	0.605	.014	7	view →
UCEC	DFS	Quartile	All	0.855	1.000	.016	4	view →
HNSC	DFS	Median	All	0.985	0.919	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

XPO5–LSCC (DFS)

Open the LSCC breakdown →